163 related articles for article (PubMed ID: 32047894)
1. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Law CCY; Koh D; Bao Y; Jairath V; Narula N
Inflamm Bowel Dis; 2020 Nov; 26(12):1796-1807. PubMed ID: 32047894
[TBL] [Abstract][Full Text] [Related]
2. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.
Law CC; Bell C; Koh D; Bao Y; Jairath V; Narula N
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013256. PubMed ID: 33098570
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
[TBL] [Abstract][Full Text] [Related]
4. Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.
Park J; Cheon JH
Korean J Intern Med; 2022 Sep; 37(5):895-905. PubMed ID: 35882566
[TBL] [Abstract][Full Text] [Related]
5. The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.
Yu CS; Jung SW; Lee JL; Lim SB; Park IJ; Yoon YS; Kim CW; Yang SK; Ye BD; Park SH; Han M; Kim JC
Inflamm Bowel Dis; 2019 Aug; 25(9):1559-1568. PubMed ID: 30753560
[TBL] [Abstract][Full Text] [Related]
6. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.
Aberra FN; Lewis JD; Hass D; Rombeau JL; Osborne B; Lichtenstein GR
Gastroenterology; 2003 Aug; 125(2):320-7. PubMed ID: 12891531
[TBL] [Abstract][Full Text] [Related]
8. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
9. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients.
Lightner AL; Grass F; Alsughayer AM; Harmsen WS; Petersen M; Loftus EV
Dis Colon Rectum; 2020 Jul; 63(7):934-943. PubMed ID: 32149787
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients.
Moosvi Z; Duong J; Bechtold ML; Nguyen DL
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):799-816. PubMed ID: 33079779
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor Necrosis Factor Alpha Versus Corticosteroids: A 3-fold Difference in the Occurrence of Venous Thromboembolism in Inflammatory Bowel Disease－A Systematic Review and Meta-analysis.
Székely H; Tóth LM; Rancz A; Walter A; Farkas N; Sárközi MD; Váncsa S; Erőss B; Hegyi P; Miheller P
J Crohns Colitis; 2024 May; 18(5):773-783. PubMed ID: 37952112
[TBL] [Abstract][Full Text] [Related]
13. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.
Dhindsa BS; Dhaliwal A; Mashiana HS; Saghir SM; Sayles H; Mubder M; Ohning G; Eichele D
Indian J Gastroenterol; 2020 Apr; 39(2):153-160. PubMed ID: 32468382
[TBL] [Abstract][Full Text] [Related]
14. The Association of Medications and Vaccination with Risk of Pneumonia in Inflammatory Bowel Disease.
Gregory MH; Ciorba MA; Wiitala WL; Stidham RW; Higgins P; Morley SC; Hou JK; Feagins LA; Govani SM; Cohen-Mekelburg SA; Waljee AK
Inflamm Bowel Dis; 2020 May; 26(6):919-925. PubMed ID: 31504531
[TBL] [Abstract][Full Text] [Related]
15. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.
Narula N; Charleton D; Marshall JK
Aliment Pharmacol Ther; 2013 Jun; 37(11):1057-64. PubMed ID: 23581515
[TBL] [Abstract][Full Text] [Related]
17. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
18. Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.
Qiu Y; Zheng Z; Liu G; Zhao X; He A
United European Gastroenterol J; 2019 Nov; 7(9):1198-1214. PubMed ID: 31700633
[TBL] [Abstract][Full Text] [Related]
19. Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease.
Andersson P; Karling P
Ups J Med Sci; 2022; 127():. PubMed ID: 35140875
[TBL] [Abstract][Full Text] [Related]
20. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
Park KT; Sceats L; Dehghan M; Trickey AW; Wren A; Wong JJ; Bensen R; Limketkai BN; Keyashian K; Kin C
Aliment Pharmacol Ther; 2018 Aug; 48(3):340-346. PubMed ID: 29876995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
